1. Introduction

Strategic Biological Asset Protection refers to the legal, institutional, technological and security measures adopted by governments to protect biological resources that are essential to national security, public health, food security, scientific development and economic sovereignty.

Strategic biological assets include:

Human genetic databases and genomic information.

Pathogen collections, viruses, bacteria and other microorganisms.

Biological research laboratories and high-containment facilities.

Genetically modified organisms (GMOs).

Indigenous biological resources and traditional medicinal knowledge.

Seed banks, agricultural germplasm and livestock genetic resources.

Stem-cell repositories, tissue banks and biobanks.

Biotechnology manufacturing facilities and vaccine production systems.

Synthetic biology platforms and engineered biological materials.

National biological surveillance and disease-monitoring infrastructure.

These assets have enormous scientific and economic value. However, their misuse, theft, unauthorized transfer, deliberate release or exploitation may threaten national security, biodiversity, public health and economic independence.

Strategic biological asset protection therefore seeks to establish a legal framework that balances national sovereignty, scientific freedom, intellectual property rights, public health, biosecurity and international cooperation.

2. Meaning and Legal Nature of Strategic Biological Assets

Strategic biological assets are biological materials, information systems, infrastructure or technological capabilities that possess exceptional national importance.

Their legal nature varies according to the asset.

A government cannot automatically claim ownership over every biological material located within its territory. Ownership, access, custody, regulatory authority and sovereign rights are legally distinct concepts.

For example, a biological sample may belong to a research institution, contain information relating to an individual, originate from a community's traditional knowledge and remain subject to government biosafety regulation.

This creates overlapping legal responsibilities.

3. Objectives of Strategic Biological Asset Protection

A. Protection of national biological sovereignty

States seek to regulate access to biological resources located within their jurisdiction.

The Convention on Biological Diversity (CBD), 1992, recognizes national sovereign rights over natural resources and establishes principles governing access to genetic resources.

Its principal objectives include:

Conservation of biological diversity.

Sustainable use of biological resources.

Fair and equitable sharing of benefits arising from genetic-resource utilization.

B. Prevention of biological theft and unauthorized exploitation

Unauthorized collection, export, duplication or commercial exploitation of biological resources can undermine national economic interests.

Legal protection may include:

Export permits.

Access-and-benefit-sharing agreements.

Research authorization.

Material transfer agreements.

Intellectual property safeguards.

Customs monitoring.

Institutional compliance audits.

C. Protection against biological threats

Pathogens and engineered organisms may create serious risks if improperly handled.

Protection mechanisms include laboratory access restrictions, pathogen inventories, containment requirements, personnel screening where lawful, incident reporting and emergency-response arrangements.

D. Protection of public health

National vaccine repositories, diagnostic technologies, biological manufacturing facilities and disease-surveillance systems are essential public-health assets.

Their protection helps maintain continuity during pandemics, biological emergencies and international supply-chain disruptions.

4. International Legal Framework

A. Convention on Biological Diversity, 1992

The CBD is one of the most important international instruments governing biological asset protection.

Its key provisions include:

Article 3: States have sovereign rights over their natural resources, subject to responsibility not to cause environmental damage beyond their jurisdiction.

Article 8: Requires in-situ conservation of biological diversity.

Article 15: Establishes the framework for access to genetic resources and benefit-sharing.

Article 16: Addresses access to and transfer of technology.

Article 19: Deals with biotechnology and the distribution of its benefits.

The Convention provides an important foundation for preventing unauthorized exploitation of national biological resources.

B. Nagoya Protocol, 2010

The Nagoya Protocol establishes rules for access to genetic resources and fair and equitable benefit-sharing.

Its major principles include:

Prior informed consent where applicable.

Mutually agreed terms.

Fair sharing of monetary and non-monetary benefits.

Protection of traditional knowledge associated with genetic resources.

Cooperation between countries concerning cross-border genetic resources.

For example, if a foreign pharmaceutical company obtains a medicinal plant from an indigenous community and develops a commercially successful medicine, applicable access and benefit-sharing obligations may arise.

Official treaty: Full text of the Nagoya Protocol.

C. Cartagena Protocol on Biosafety, 2000

The Cartagena Protocol on Biosafety regulates the safe handling, transport and use of living modified organisms (LMOs).

Its important provisions include:

Article 8: Notification requirements.

Article 10: Decision-making procedure.

Article 15: Risk assessment.

Article 16: Risk management.

Article 17: Unintentional transboundary movements and emergency measures.

Article 18: Handling, transport, packaging and identification.

It provides a framework for protecting biological assets from risks associated with biotechnology and international movement of modified organisms.

Official treaty: Cartagena Protocol full text.

Biosafety Clearing-House+1

D. Biological Weapons Convention, 1972

The Biological Weapons Convention prohibits the development, production, stockpiling, acquisition and retention of biological agents and toxins for prohibited purposes.

Article I prohibits biological agents and toxins of types and quantities that have no justification for prophylactic, protective or other peaceful purposes.

Article IV requires states to take necessary national measures to prohibit and prevent prohibited activities within their jurisdiction.

This Convention is particularly important for preventing strategic biological materials from being diverted towards biological weapons programmes.

E. International Health Regulations, 2005

The International Health Regulations establish international obligations concerning public-health surveillance, notification and response to events that may constitute international public-health emergencies.

They support the protection of national disease-surveillance systems, laboratory networks and public-health infrastructure.

5. Indian Legal Framework for Strategic Biological Asset Protection

India has developed a combination of biodiversity, environmental, biotechnology, intellectual property, public-health and data-protection laws.

A. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 is a central legislative instrument for protecting India's biological resources.

Its major institutional mechanisms are:

National Biodiversity Authority (NBA).

State Biodiversity Boards (SBBs).

Biodiversity Management Committees (BMCs).

Important provisions include:

The Biological Diversity (Amendment) Act, 2023 introduced significant changes to the regulatory framework, including changes concerning access, benefit-sharing and exemptions.

The legislation must therefore be read in its amended form, together with applicable rules and regulations.

B. Environment (Protection) Act, 1986

This Act provides the general statutory foundation for environmental protection.

It supports regulatory action concerning hazardous biological activities and environmentally dangerous processes.

The Environment (Protection) Rules, 1986 and the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms/Genetically Engineered Organisms or Cells, 1989 are particularly relevant to biotechnology regulation.

C. Biological Safety and GMO Regulation

India's 1989 Rules establish regulatory arrangements for genetically engineered organisms and hazardous microorganisms.

Important authorities include:

Genetic Engineering Appraisal Committee (GEAC).

Review Committee on Genetic Manipulation (RCGM).

Institutional Biosafety Committees (IBSCs).

State Biotechnology Coordination Committees (SBCCs).

District Level Committees (DLCs).

These bodies perform different functions relating to research oversight, risk assessment, approvals, monitoring and enforcement.

D. Digital Personal Data Protection Act, 2023

Biological asset protection increasingly involves genomic and genetic information.

The Digital Personal Data Protection Act, 2023 is relevant where digital biological information constitutes personal data and falls within its territorial and substantive scope.

Genetic information can reveal highly sensitive information about individuals and their biological relatives. Consequently, lawful processing, security safeguards, access control and applicable consent requirements are important.

The Act does not, however, establish a comprehensive standalone genetic-data ownership regime.

E. Patents Act, 1970

The Patents Act protects qualifying biotechnology inventions while imposing important restrictions.

Relevant provisions include:

Section 3(c): Excludes the discovery of a living thing or non-living substance occurring in nature from patentability.

Section 3(j): Excludes plants and animals in whole or any part thereof, other than microorganisms, and essentially biological processes for production or propagation of plants and animals.

Section 3(i): Addresses certain methods of medical treatment.

Section 6: Deals with persons entitled to apply for patents.

Section 10: Establishes requirements concerning patent specifications.

These provisions help distinguish naturally occurring biological resources from patentable human inventions.

6. Important Judicial Decisions and Case Laws

The following cases establish important principles concerning biological ownership, genetic resources, biotechnology patents, informed consent and protection against unauthorized exploitation.

Case 1. Divya Pharmacy v. Union of India (2018)

Court: Uttarakhand High Court, India.

Facts:

Divya Pharmacy manufactured Ayurvedic and pharmaceutical products using Indian biological resources. The Uttarakhand Biodiversity Board demanded fair and equitable benefit-sharing payments.

The company challenged the demand, arguing that the benefit-sharing obligation did not apply to an Indian company without foreign participation.

Legal issue:

Whether an Indian company commercially utilizing biological resources could be required to share benefits under the Biological Diversity Act, 2002.

Judgment:

The High Court rejected the challenge and upheld the State Biodiversity Board's authority to impose applicable fair and equitable benefit-sharing obligations.

Legal principles:

Indian biological resources require statutory protection.

Commercial utilization may attract benefit-sharing obligations.

Biodiversity protection is not restricted to preventing foreign exploitation.

Indigenous communities and local resource custodians have an important role in biodiversity governance.

Importance: This is a particularly important Indian precedent for strategic biological asset protection because it recognizes that domestic commercial enterprises can also have obligations towards conservation and equitable benefit-sharing.

National Biodiversity Authority+2

Case 2. Moore v. Regents of the University of California (1990)

Citation: 51 Cal. 3d 120; 793 P.2d 479.

Court: Supreme Court of California, United States.

Facts:

John Moore underwent treatment for leukemia. His physician obtained biological samples from him and used them in research that ultimately resulted in the development of a commercially valuable cell line.

Moore alleged that his physician had failed to disclose the research and financial interests associated with his biological material.

Legal issue:

Whether a patient retained proprietary rights over removed biological cells and whether undisclosed commercial interests violated the physician's legal duties.

Judgment:

The Court rejected Moore's conversion claim concerning the removed cells but allowed claims based on breach of fiduciary duty and lack of informed consent to proceed.

Legal principles:

Informed consent is essential in medical research.

Physicians must disclose material financial and research interests.

Commercially valuable biological research does not automatically establish ownership rights in the original tissue donor.

Researchers must respect the legal duties owed to biological material donors.

Importance: This case is fundamental to the protection of human biological samples, biobanks, tissue repositories and genomic research programmes.

Justia Law+1

Case 3. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Court: United States District Court, Southern District of Florida.

Facts:

Families and researchers collaborated in research concerning Canavan disease. Biological samples and genetic information were provided to support research into the disease.

The research resulted in patent-related and commercial disputes.

Legal issue:

Whether donors and contributors could claim ownership or control over the resulting genetic discoveries and research developments.

Judgment:

The Court rejected the plaintiffs' conversion and unjust-enrichment theories in the circumstances, while recognizing the importance of disclosure and the parties' legal obligations.

Legal principles:

Donating biological samples does not automatically confer ownership of subsequent scientific discoveries.

Research agreements and representations concerning sample use are legally important.

Scientific collaboration can generate complex benefit-sharing and intellectual property disputes.

Informed disclosure is essential in genetic research.

Importance: The judgment highlights the need for clear biological sample donation agreements, research-use restrictions and commercial benefit-sharing arrangements.

Case 4. Association for Molecular Pathology v. Myriad Genetics (2013)

Citation: 569 U.S. 576 (2013).

Court: Supreme Court of the United States.

Facts:

Myriad Genetics obtained patents relating to the BRCA1 and BRCA2 genes associated with increased risks of breast and ovarian cancer.

The patent claims raised questions concerning ownership and patentability of naturally occurring genetic sequences.

Legal issue:

Whether naturally occurring human DNA could be patented merely because it had been isolated from the human body.

Judgment:

The Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated.

However, synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the ordinary requirements of patent law.

Legal principles:

Natural genetic information cannot automatically become private intellectual property through isolation.

Scientific discoveries must be distinguished from human inventions.

Patent rights must not improperly monopolize naturally occurring biological information.

Importance: This case is significant for national genomic sovereignty, public access to genetic testing, biotechnology research and the prevention of excessive privatization of biological resources.

Case 5. Diamond v. Chakrabarty (1980)

Citation: 447 U.S. 303 (1980).

Court: Supreme Court of the United States.

Facts:

An inventor developed a genetically engineered bacterium capable of breaking down multiple components of crude oil.

The invention raised the question of whether a living genetically modified microorganism could qualify as patentable subject matter.

Legal issue:

Whether a human-made genetically modified microorganism could be patented.

Judgment:

The Supreme Court recognized that the genetically engineered microorganism could qualify for patent protection because it was a product of human ingenuity rather than merely a naturally occurring organism.

Legal principles:

Human-made biological inventions may qualify for patent protection.

Naturally occurring organisms and engineered biological inventions must be distinguished.

Biotechnology innovation can receive intellectual property protection.

Patent protection remains subject to applicable statutory limitations.

Importance: This case provides a foundation for protecting strategically important biotechnology inventions while maintaining the distinction between biological resources and human-created innovations.

Case 6. Monsanto Canada Inc. v. Schmeiser (2004)

Citation: [2004] 1 SCR 902.

Court: Supreme Court of Canada.

Facts:

Percy Schmeiser, a Canadian farmer, was found to have cultivated canola containing Monsanto's patented Roundup Ready genetic technology.

The dispute concerned patent infringement and the commercial use of genetically modified plant technology.

Legal issue:

Whether unauthorized cultivation or use of patented genetically engineered material could constitute patent infringement.

Judgment:

The Supreme Court found patent infringement on the particular facts. It also held that Schmeiser had not obtained a financial benefit from the patented invention and therefore no monetary damages were awarded.

Legal principles:

Biotechnology patents can protect qualifying engineered genetic inventions.

Unauthorized commercial exploitation may create infringement liability.

Patent protection does not necessarily confer ownership over every plant containing patented genetic material.

The economic benefit obtained by the alleged infringer is relevant to remedies.

Importance: This case is relevant to the protection of agricultural germplasm, seed technologies, national seed systems and biotechnology intellectual property.

7. Institutional Mechanisms for Strategic Biological Asset Protection

Effective protection requires coordination between government institutions, research organizations, regulatory agencies and private biotechnology enterprises.

A. National biological asset registry

Governments should establish legally regulated inventories of strategically important biological assets.

These may include:

National pathogen repositories.

Genomic and genetic databases.

Seed and germplasm banks.

Vaccine research collections.

Publicly funded biological research assets.

Important biotechnology infrastructure.

Such registries should maintain appropriate confidentiality and privacy protections.

B. Access-control systems

Biological repositories and laboratories should use legally authorized access systems.

These may include:

Personnel authorization.

Institutional approval.

Visitor monitoring.

Sample movement records.

Research-purpose verification.

Periodic compliance audits.

C. Material Transfer Agreements

Material Transfer Agreements (MTAs) regulate the transfer and use of biological materials between institutions.

An effective MTA should address:

Identity and description of biological material.

Permitted research purposes.

Restrictions on onward transfer.

Intellectual property ownership.

Publication rights.

Confidentiality.

Benefit-sharing obligations.

Return or destruction of materials.

Liability for unauthorized use.

Applicable law and dispute resolution.

D. Protection of biological infrastructure

National authorities should ensure that important biological facilities have:

Physical security.

Laboratory safety systems.

Disaster recovery arrangements.

Backup power and storage.

Cybersecurity protections.

Incident-response mechanisms.

Emergency continuity plans.

E. Protection against cyber theft

Modern biological assets are increasingly stored in digital systems.

Genomic databases, laboratory information systems and synthetic biology research platforms can be targeted through cyberattacks.

Legal safeguards should address unauthorized access, data extraction, alteration, destruction and unlawful disclosure.

Importantly, biological data security must also protect individual privacy and prevent discriminatory use of genetic information.

8. Strategic Biological Asset Protection and National Security

Biological assets may have strategic importance beyond ordinary commercial value.

A. Protection against biological espionage

Biological espionage involves unauthorized acquisition of confidential biological research, pathogen-related information, genetic resources or biotechnology developments.

Legal responses may involve:

National security legislation.

Intellectual property enforcement.

Cybersecurity laws.

Research confidentiality obligations.

Export-control regulations.

B. Protection of national genomic databases

National genomic databases may contain information relating to inherited diseases, population genetics, ancestry and biological characteristics.

Governments should establish safeguards concerning:

Lawful collection and processing.

Informed consent where required.

Restricted access.

Data minimization.

Cross-border transfers.

Unauthorized commercial exploitation.

Retention and deletion policies.

C. Protection of strategic pathogen collections

Pathogen repositories require appropriate containment, inventory management, personnel accountability and emergency procedures.

The Biological Weapons Convention is particularly relevant where biological materials could be diverted towards prohibited weapons purposes.

D. Protection of national seed resources

Agricultural biodiversity is essential for food security.

National governments should protect indigenous seed varieties, traditional agricultural knowledge, seed banks and germplasm collections through biodiversity legislation, plant variety protection and appropriate conservation programmes.

9. Liability for Failure to Protect Biological Assets

Different forms of legal liability may arise when strategic biological assets are improperly managed.

Liability should be based on the relevant statutory provisions, the nature of the biological asset, the conduct involved and the applicable jurisdiction.

10. Major Legal Challenges

1. Conflict between national sovereignty and scientific freedom

Governments may impose restrictions on biological resource access in the national interest. Excessive restrictions, however, can obstruct legitimate scientific collaboration.

2. Ownership of biological materials

It is difficult to determine who owns biological samples obtained from individuals, indigenous communities, research institutions or public repositories.

The Moore and Greenberg decisions demonstrate that biological sample donation, ownership of resulting discoveries and commercial benefit-sharing are separate legal questions.

3. Cross-border biological exploitation

Biological materials may be collected in one country, researched in another and commercially exploited in a third.

This creates disputes concerning applicable law, access authorization, benefit-sharing and intellectual property rights.

4. Conflict between patent rights and public interest

Patents encourage biotechnology innovation but may restrict access to important genetic technologies.

Governments must balance commercial incentives with public health, food security and biodiversity conservation.

5. Weak enforcement mechanisms

Biological materials may be difficult to trace once transferred between multiple laboratories or commercial entities.

Effective enforcement requires institutional cooperation, reliable documentation and appropriate regulatory oversight.

6. Emerging synthetic biology technologies

Synthetic biology creates new questions concerning engineered organisms, biological design information, intellectual property, environmental risk and responsibility for unintended consequences.

Existing laws may not adequately address every new technological development.

11. Recommendations for Strengthening Strategic Biological Asset Protection

A comprehensive legal framework should incorporate the following measures:

1. National biological asset classification: Identify biological materials according to their scientific, environmental, public-health and national-security importance.

2. Mandatory institutional accountability: Require appropriate authorization, documentation and periodic audits for regulated biological repositories.

3. Strong access-and-benefit-sharing mechanisms: Ensure fair benefits for local communities and other legally recognized stakeholders.

4. International cooperation: Develop agreements concerning the lawful transfer, conservation and use of genetic resources.

5. Genomic privacy safeguards: Establish strong protections against unauthorized collection, disclosure and commercial exploitation of personal genetic information.

6. Biological infrastructure protection: Strengthen the physical security, cybersecurity and operational resilience of strategically important facilities.

7. Clear ownership and custody rules: Distinguish ownership, possession, custodianship, intellectual property and regulatory control.

8. Effective judicial remedies: Provide accessible mechanisms for challenging unlawful transfers, regulatory failures and unauthorized exploitation.

9. Public-private accountability: Establish contractual and statutory obligations for private biotechnology companies handling nationally significant biological assets.

10. Periodic legislative review: Update biological security legislation to address advances in artificial intelligence, synthetic biology, genomic engineering and biotechnology manufacturing.

12. Critical Legal Analysis

Strategic Biological Asset Protection should not be interpreted as giving governments unlimited ownership or control over all biological materials.

There are several competing legal interests:

State sovereignty: Governments have regulatory authority over biological resources within their jurisdiction, subject to international obligations.

Individual autonomy: Human biological samples and personal genetic information raise important consent and privacy concerns.

Community rights: Indigenous and local communities may have legally recognized interests in biological resources and associated traditional knowledge.

Scientific freedom: Legitimate research should not be unnecessarily restricted.

Commercial interests: Biotechnology companies may hold valid intellectual property rights over qualifying inventions.

Public interest: Biological resources should be managed in ways that support public health, environmental conservation and food security.

The central legal challenge is therefore to create a framework that protects strategic biological resources without undermining human rights, scientific progress and equitable access.

13. Conclusion

Strategic Biological Asset Protection is an emerging and important area of biotechnology, environmental and national security law.

The Convention on Biological Diversity, Nagoya Protocol, Cartagena Protocol and Biological Weapons Convention provide important international foundations. In India, the Biological Diversity Act, 2002, the Environment (Protection) Act, 1986, the Patents Act, 1970 and applicable data-protection and biosafety legislation provide complementary legal safeguards.

The judicial decisions in Divya Pharmacy, Moore, Greenberg, Myriad Genetics, Diamond v. Chakrabarty and Monsanto Canada v. Schmeiser demonstrate that biological asset protection involves more than ownership. It also involves informed consent, regulatory control, benefit-sharing, intellectual property, national sovereignty and responsible scientific use.

Ultimately, strategic biological asset protection requires a balance between national biological sovereignty, individual rights, environmental security, scientific innovation and public welfare.

14. Important Legal References for Further Study

Research note: The cases above are from different jurisdictions and are not all binding precedents in India. They are useful comparative authorities. The precise application of Indian law also depends on the amendments, rules and regulations in force when the relevant conduct occurs.

For further legal research, the most useful primary materials are the Divya Pharmacy judgment, Moore judgment, Nagoya Protocol and Cartagena Protocol.